AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36519982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position during ECMO
Number of subjects: 517
Study 36519984 — intervention group
Group type: EXPERIMENTAL
Intervention: astegolimab
Number of subjects: 396
Study 36519984 — intervention group
Group type: EXPERIMENTAL
Intervention: efmarodocokin alfa
Number of subjects: 396
Study 36519984 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 396
Study 36520008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide (median 5.1 years)
Number of subjects: 0
Study 36520008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide (more than 9 years in 34 patients in Italy)
Number of subjects: 0
Study 36520008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide (phase 3 trial and LOWER registry)
Number of subjects: 0
Study 36520162 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 T-R2* LIC
Number of subjects: 30
Study 36520162 — intervention group
Group type: COMPARATOR
Intervention: 1.5 T-R2* LIC
Number of subjects: 30
Study 36520177 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain
Number of subjects: 144
Study 36520177 — intervention group
Group type: COMPARATOR
Intervention: No Drain
Number of subjects: 144
Study 36520251 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-Advance Intervention (PAI): 1 night of late-night wake therapy (LWT: sleep 9 pm-1 am) followed by 7 days of morning bright white light (BWL)
Number of subjects: 44
Study 36520251 — intervention group
Group type: COMPARATOR
Intervention: Phase-Delay Intervention (PDI): 1 night of early-night wake therapy (EWT: sleep 3-7 am) plus 7 days of evening BWL
Number of subjects: 44
Study 36520325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine (Boostrix) administered on or after the 27th week of pregnancy
Number of subjects: 16350
Study 36520325 — intervention group
Group type: COMPARATOR
Intervention: No Tdap vaccine during pregnancy (control group)
Number of subjects: 16350
Study 36520426 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg plus Bevacizumab 15 mg/kg on day 1 of each 21-day cycle until disease progression or unacceptable toxic effects.
Number of subjects: 38
Study 36520462 — intervention group
Group type: EXPERIMENTAL
Intervention: SB11 (0.5 mg)
Number of subjects: 705
Study 36520462 — intervention group
Group type: COMPARATOR
Intervention: RBZ (0.5 mg)
Number of subjects: 705
Study 36520462 — intervention group
Group type: EXPERIMENTAL
Intervention: SB11
Number of subjects: 705
Study 36520519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tappt digital health system (RTM)
Number of subjects: 123
Study 36520519 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 123
Study 36520613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 36520613 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 36520715 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily for six additional weeks
Number of subjects: 402
Study 36520715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 36520813 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan coated suture (TCS)
Number of subjects: 380
Study 36520813 — intervention group
Group type: COMPARATOR
Intervention: Non-coated suture VICRYL
Number of subjects: 380
Study 36520927 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate-level response screening format
Number of subjects: 367
Study 36520927 — intervention group
Group type: COMPARATOR
Intervention: Item-level response screening format
Number of subjects: 367
Study 36521030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pola-DA-EPCH-R (vincristine omitted)
Number of subjects: 18
Study 36521078 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Exemestane with Ovarian Suppression
Number of subjects: 0
Study 36521078 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36521097 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment
Number of subjects: 866
Study 36521100 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Illness Care Program (SICP) delivered via telehealth
Number of subjects: 45
Study 36521103 — intervention group
Group type: EXPERIMENTAL
Intervention: SurVaxM plus adjuvant temozolomide (TMZ)
Number of subjects: 64
Study 36521131 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative couple treatment for pathological gambling (ICT-PG)
Number of subjects: 80
Study 36521131 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment approach
Number of subjects: 80
Study 36521262 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled single-dose MK-5475 (120 μg and 360 μg)
Number of subjects: 0
Study 36521262 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled single-dose MK-5475
Number of subjects: 0
Study 36521330 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 568
Study 36521330 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling nervous
Number of subjects: 568
Study 36521330 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease
Number of subjects: 568
Study 36521330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbances
Number of subjects: 568
Study 36521330 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 568
Study 36521330 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe disease course
Number of subjects: 568
Study 36521330 — intervention group
Group type: EXPERIMENTAL
Intervention: Third pandemic wave
Number of subjects: 568
Study 36521330 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness during the fourth wave
Number of subjects: 568
Study 36521330 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness during the fifth wave
Number of subjects: 568
Study 36521330 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 568
Study 36521501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegozafermin 3 mg once weekly
Number of subjects: 81
Study 36521501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegozafermin 9 mg once weekly
Number of subjects: 81
Study 36521501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegozafermin 18 mg once weekly
Number of subjects: 81
Study 36521501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegozafermin 27 mg once weekly
Number of subjects: 81
Study 36521501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegozafermin 18 mg once every 2 weeks
Number of subjects: 81
Study 36521501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegozafermin 36 mg once every 2 weeks
Number of subjects: 81
Study 36521501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 36521580 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodilatation with 40 mg triamcinolone acetonide (TA)
Number of subjects: 84
Study 36521580 — intervention group
Group type: COMPARATOR
Intervention: Hydrodilatation with 10 mg triamcinolone acetonide (TA)
Number of subjects: 84
Study 36521694 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-beta ratio neurofeedback (NF)
Number of subjects: 142
Study 36521694 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (identical appearance, intensity/frequency, and duration)
Number of subjects: 142
Study 36521802 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of peanut products at 4 months for infants with eczema
Number of subjects: 2137
Study 36521802 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of peanut products at 6 months for infants without eczema
Number of subjects: 2137
Study 36521802 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed introduction of peanut products to 12 months
Number of subjects: 2137
Study 36521802 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting only the highest-risk infants with severe eczema
Number of subjects: 2137
Study 36521878 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudoscan
Number of subjects: 2243
Study 36521878 — intervention group
Group type: COMPARATOR
Intervention: Monofilament test
Number of subjects: 2243
Study 36521878 — intervention group
Group type: COMPARATOR
Intervention: Tuning fork test
Number of subjects: 2243
Study 36521878 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 2243
Study 36521884 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI parameters (T2-weighted and diffusion tensor images)
Number of subjects: 115
Study 36521884 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Disability Index and self-rated global recovery question
Number of subjects: 115
Study 36521884 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing and skin biopsies
Number of subjects: 115
Study 36521884 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 115
Study 36521884 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear and logistic regression analyses
Number of subjects: 115
Study 36521884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed effects modelling
Number of subjects: 115
Study 36521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised StayFine app plus monitoring
Number of subjects: 254
Study 36521888 — intervention group
Group type: COMPARATOR
Intervention: Monitoring only
Number of subjects: 254
Study 36521888 — intervention group
Group type: EXPERIMENTAL
Intervention: StayFine modules
Number of subjects: 254
Study 36521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to relapse (primary outcome)
Number of subjects: 254
Study 36521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression and anxiety (secondary outcome)
Number of subjects: 254
Study 36521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Number and duration of relapses (secondary outcome)
Number of subjects: 254
Study 36521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Global functioning (secondary outcome)
Number of subjects: 254
Study 36521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (secondary outcome)
Number of subjects: 254
Study 36521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediators and moderators
Number of subjects: 254
Study 36521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and wearable outcomes (exploratory endpoints)
Number of subjects: 254
Study 36521957 — intervention group
Group type: EXPERIMENTAL
Intervention: Government funding through balance allocation
Number of subjects: 660565
Study 36521957 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial problems that interrupted routine service delivery
Number of subjects: 660565
Study 36521957 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting performance-based bonus
Number of subjects: 660565
Study 36521957 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic salary defined by number of patient visits
Number of subjects: 660565
Study 36521957 — intervention group
Group type: EXPERIMENTAL
Intervention: Using electronic referrals
Number of subjects: 660565
Study 36521957 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementing family physician contract services
Number of subjects: 660565
Study 36521957 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of physicians who are formally licensed
Number of subjects: 660565
Study 36522265 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed V114/PCV13 regimen
Number of subjects: 900
Study 36522265 — intervention group
Group type: EXPERIMENTAL
Intervention: Toddler dose of V114
Number of subjects: 900
Study 36522265 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed regimens with at least one infant dose plus toddler dose of V114
Number of subjects: 900
Study 36522265 — intervention group
Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 900
Study 36522265 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 900
Study 36522279 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodynamic drug response classifier (4-level classifier)
Number of subjects: 30
Study 36522279 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodynamic scoring
Number of subjects: 30
Study 36522279 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care cytotoxins (gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 30
Study 36522365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (anti-CCR4 monoclonal antibody)
Number of subjects: 0
Study 36522365 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 0
Study 36522418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) assessment of quadriceps femoris (QF) muscle architecture
Number of subjects: 70
Study 36522434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal graft (DG)
Number of subjects: 21
Study 36522434 — intervention group
Group type: COMPARATOR
Intervention: Split-thickness skin graft (STSG)
Number of subjects: 21
Study 36522433 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure-guided ventilation with PEEP of 5 cm H2O
Number of subjects: 0
Study 36522433 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36522453 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy-based EEG biomarkers of consciousness
Number of subjects: 0
Study 36522453 — intervention group
Group type: COMPARATOR
Intervention: Spectral EEG features
Number of subjects: 0
Study 36522606 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin daily
Number of subjects: 6263
Study 36522606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study 36522658 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 5
Study 36522680 — intervention group
Group type: EXPERIMENTAL
Intervention: active tDCS
Number of subjects: 33
Study 36522680 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 33
Study 36522698 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (experimental arm of the Covidicus trial)
Number of subjects: 0
Study 36522698 — intervention group
Group type: COMPARATOR
Intervention: Recovery trial (control data)
Number of subjects: 0
Study 36522767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine plus paracetamol
Number of subjects: 0
Study 36522767 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine alone
Number of subjects: 0
Study 36522772 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual parent-led peer support groups (vPLPSGs) for 6 months
Number of subjects: 44
Study 36523131 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell exchange transfusion
Number of subjects: 3
Study 36523236 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaking Free Online (BFO) with group peer support
Number of subjects: 225
Study 36523236 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaking Free Online (BFO) alone
Number of subjects: 225
Study 36523236 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaking Free Online (BFO) with individual peer support
Number of subjects: 225
Study 36523236 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 225
Study 36523242 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated lifestyle intervention initiated at preconception and continuing throughout pregnancy and postpartum periods.
Number of subjects: 500
Study 36523250 — intervention group
Group type: EXPERIMENTAL
Intervention: theory-derived intervention
Number of subjects: 440
Study 36523250 — intervention group
Group type: COMPARATOR
Intervention: conventional health education
Number of subjects: 440
Study 36523415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant (5 μg of D614 and 5 μg of B.1.351)
Number of subjects: 12924
Study 36523415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12924
Study 36523440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic post-conditioning (0, 1, 2, 3, 4, and 5 min × 4 cycles)
Number of subjects: 3
Study 36523440 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombectomy
Number of subjects: 3
Study 36523553 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36523754 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological monitoring while watching a disturbing video (group with ASD)
Number of subjects: 40
Study 36523754 — intervention group
Group type: COMPARATOR
Intervention: Physiological monitoring while watching a relaxing video (group with ASD)
Number of subjects: 40
Study 36523754 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of 10 participants with ASD for 7 days to predict challenging behaviors (CBs)
Number of subjects: 40
Study 36523754 — intervention group
Group type: EXPERIMENTAL
Intervention: Proof of concept (POC) testing of the developed system on one participant with ASD and CB
Number of subjects: 40
Study 36523754 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group feedback on the developed system
Number of subjects: 40
Study 36524116 — intervention group
Group type: EXPERIMENTAL
Intervention: CD38-directed CAR-T cell therapy
Number of subjects: 2
Study 36524126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent booster vaccination
Number of subjects: 0
Study 36524254 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week gross motor intervention program
Number of subjects: 17
Study 36524387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach
Number of subjects: 17
Study 36524387 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 36524472 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating PAGln levels
Number of subjects: 4085
Study 36524472 — intervention group
Group type: EXPERIMENTAL
Intervention: PAGln and phenylacetylglycine
Number of subjects: 4085
Study 36524474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 30
Study 36524474 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study 36524476 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes present (109 patients)
Number of subjects: 898
Study 36524539 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management medications (specific medications not detailed)
Number of subjects: 0
Study 36524557 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester HbA1c level of 6.5% (48 mmol/mol) or more excluded from the study.
Number of subjects: 785
Study 36524557 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA1c and random plasma glucose values in women who developed GDM.
Number of subjects: 785
Study 36524557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of maternal characteristics (age, BMI, history of GDM, family history of diabetes) with HbA1c and random plasma glucose.
Number of subjects: 785
Study 36524810 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (inert pill)
Number of subjects: 0
Study 36524810 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study 36524810 — intervention group
Group type: COMPARATOR
Intervention: No-treatment arm
Number of subjects: 0
Study 36524980 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib
Number of subjects: 0
Study 36524980 — intervention group
Group type: COMPARATOR
Intervention: Investigator-selected TKI
Number of subjects: 0
Study 36525069 — intervention group
Group type: COMPARATOR
Intervention: Pilates core stability exercises program
Number of subjects: 60
Study 36525069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates core stability exercises program plus HUMAC balance program
Number of subjects: 60
Study 36525069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates core stability exercises program plus coordination exercises of BOT-2
Number of subjects: 60
Study 36525080 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Life outside work
Number of subjects: 483
Study 36525080 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Fitness
Number of subjects: 483
Study 36525080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Functions
Number of subjects: 483
Study 36525140 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplontersen (ION-682884), a ligand-conjugated antisense oligonucleotide designed to degrade hepatic TTR mRNA.
Number of subjects: 168
Study 36525147 — intervention group
Group type: EXPERIMENTAL
Intervention: Character strengths-based intervention (CSI)
Number of subjects: 0
Study 36525180 — intervention group
Group type: COMPARATOR
Intervention: TEC (docetaxel 75 mg/m2, epirubicin, and cyclophosphamide)
Number of subjects: 92
Study 36525180 — intervention group
Group type: EXPERIMENTAL
Intervention: TECM (docetaxel, epirubicin, cyclophosphamide with metformin)
Number of subjects: 92
Study 36525180 — intervention group
Group type: COMPARATOR
Intervention: TEC
Number of subjects: 92
Study 36525180 — intervention group
Group type: EXPERIMENTAL
Intervention: TECM
Number of subjects: 92
Study 36525180 — intervention group
Group type: COMPARATOR
Intervention: TEC and TECM
Number of subjects: 92
Study 36525272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) from a lean donor
Number of subjects: 41
Study 36525272 — intervention group
Group type: COMPARATOR
Intervention: Autologous placebo
Number of subjects: 41
Study 36525287 — intervention group
Group type: EXPERIMENTAL
Intervention: App promoting weight gain prevention and healthy behaviors
Number of subjects: 35
Study 36525287 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to a private Facebook group for peer support
Number of subjects: 35
Study 36525287 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires regarding health behaviors and breast cancer risk belief
Number of subjects: 35
Study 36525287 — intervention group
Group type: EXPERIMENTAL
Intervention: App rating scales
Number of subjects: 35
Study 36525287 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with approximately 20 participants
Number of subjects: 35
Study 36525338 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine plus a newly initiated oral antidepressant
Number of subjects: 764
Study 36525340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0